Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine

Journal of Clinical Pharmacology

Volumn 36, Issue 4, 1996, Pages 356-360

  Yang, Bing Bing ^a   Hounslow, Neil J ^a,c   Sedman, Allen J ^a   Forgue, S Thomas ^a,b  

^a PFIZER INC   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

^c Parke Davis   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYPHENAZONE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NORPHENAZONE; PHENAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG OXIDATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; LIVER METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

EID: 0029995258     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04212.x     Document Type: Article

References (18)

1. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
2. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, et al: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
3. Bocan TMA, Ferguson E, McNally W, Uhlendorf PD, Mueller SB, Dehart P, et al: Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selective HMG-CoA reductase inhibitors. Biochim Biophys Acta 1992;1123: 133-144.
4. Vesell ES: The antipyrine test in clinical pharmacology: Conceptions and misconceptions. Clin Pharmacol Ther 1979;26:275-286.
5. Poulsen HE, Loft S: Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 1988;6:374-382.
6. Hartleb M: Drugs and the liver. II. The role of the antipyrine test in drug metabolism studies. Biopharm Drug Dispos 1991;12: 559-570.
7. Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
8. Jungnickel PW, Cantral KA, Maloley PA: Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin Pharm 1992;11:677-689.
9. Boccuzzi SJ, Keegan ME, Hirsch LJ, Shapiro DR, Plotkin DJ, Mitchel YB: Long term experience with simvastatin. Drug Invest 1993;5:135-140.
10. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalency of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
11. Danhof M, Idle JR, Teunissen MWE, Sloan TP, Breimer DD, Smith RL: Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology 1981;22:349-358.
12. Danhof M, Verbeek RMA, van Boxtel CJ, Boeijinga JK, Breimer DD: Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol 1982;13:379-386.
13. Toverud E-L, Boobis AR, Brodie MJ, Murray S, Bennett PN, Whitmarsh V, Davies DS: Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol 1981;21:155-160.
14. Shaw PN, Houston JB, Rowland M, Hopkins K, Thiercelin JF, Morselli PL: Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. Br J Clin Pharmacol 1985;20:611-618.
15. Teunissen MWE, De Leede LGJ, Boeijinga JK, Breimer DD: Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state. J Pharmacol Exp Ther 1985;233: 770-775.
16. Engel G, Hofmann U, Heidemann H, Eichelbaum M. Identification of cytochrome P450 enzymes involved in the metabolism of antipyrine: potential and limitations of different in vitro techniques (abstract). Naunyn Schmiedebergs Arch Pharmacol 1994;349(suppl):R133.
17. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome p450 enzymes catalyzing 4-hydroxy-3-hydroxymethyl- and norantipyrine formation. Clin Pharmacol Ther (in press)
18. Bowles SK, Cardozo L, Edwards DJ: Quinidine does not alter antipyrine metabolism. J Clin Pharmacol 1990;30:267-271.